Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00482170 | Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept | PHASE3 | COMPLETED | 421 | — | — | Sep 1, 2007 | Sep 1, 2009 | Mar 30, 2012 | 78 | Belgium, Denmark +10 |
Participant satisfaction was assessed by asking the question, "How satisfied are you with your injection device?" using a 0-10 point scale, where 0= totally dissatisfied and 10= totally satisfied.
Participant satisfaction was assessed by asking the question, "How satisfied are you with your injection device?" using a 0-10 point scale, where 0= totally dissatisfied and 10= totally satisfied.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Arm 1: Enbrel 50 mg Prefilled Syringe |
| 2 | ACTIVE_COMPARATOR | Arm 2 Enbrel 50 mg Autoinjector |
| Name | Type | Description |
|---|---|---|
| Enbrel (etanercept) | DEVICE | Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly |
| Etanercept | DEVICE | Arm 2 = Enbrel 50 mg Autoinjector twice weekly |
Inclusion Criteria: * Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA * Eligible for treatment with etanercept according to Summary of P...